Indoco Remedies is locked at upper circuit limit at Rs. 206.40, up by 34.40 points or 20.00% from its previous closing of Rs. 172.00 on the BSE.
The scrip opened at Rs. 172.05 and has touched a high and low of Rs. 206.40 and Rs. 167.05 respectively. So far 57721 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 317.00 on 24-Jan-2018 and a 52 week low of Rs. 150.25 on 08-Oct-2018.
Last one week high and low of the scrip stood at Rs. 206.40 and Rs. 159.25 respectively. The current market cap of the company is Rs. 1901.98 crore.
The promoters holding in the company stood at 58.87%, while Institutions and Non-Institutions held 14.97% and 26.16% respectively.
US Food and Drug Administration (USFDA) has inspected Indoco Remedies’ Sterile facility (Plant II) and Solid Dosages facility (Plant III) situated at Goa from November 14 to 21, 2018. The inspection concluded with Indoco receiving 2 minor observations, none of which are repeat in nature.
Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.
